Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
Not bad really, I know it's a bit disappointing but at least we're up compared to last week close. Inching closer to 300 without any news on sales.
Honestly, I also think this share price is being suppressed badly. Either the MM is loading up themselves, or they're filling large broke orders. Any rise is really quickly brought back down. That can be traders, but it's so regularly traded sideways it looks more like deals being done.
Anyway, I'll take anything, so 3.6% over last week's close is good enough for me to have a rum :)
Nailed it. Whole thing reads like an advert for NCYT's last RNS. Nice one Bram!
@ infor I hope you're wrong too, I really want a July sales update with US contract figures! Because like..
@ Mehta says, NCYT is past the point of having potential. It's more grown up now, actually making sales and having to prove its share price. The innovation is great for building interest though between the sales growth. This share can definitely be £5. Just needs to have the contracts there in black and white going well into 2021.
The trial's success isn't related to the launch of the Near Patient Testing system.
The NPT will be launched by the end of next week.
The Care Home trial is designed to see if it's more effective than current testing regimes in that setting.
That's how we square the RNS. There's no condition attached and we've simply assumed the two are related as we're used to successful trials being needed to launch products.
The product has already been extensively tested and is ready for market. This particular trial and its timing merely confused things as they overlap.
So, next week is the scheduled Near Patient Testing launch, barring any unforseen delay and the trial will run into the first week of September (40 days). The 21 active days refers to how many days within that 40 that tests will be carried out (not how many days have already passed in the trial).
Next week will be a good week! Then first week in August will be July sales I think right? That should give us the momentum we need. I know everyone's disappointed today, but it's momentum NCYT needs, not a single RNS. We're close, hang in there another week guys :)
https://twitter.com/PrimerdesignLtd/status/1286222247099760640?s=20
Just tweeted this around 40 mins ago. Asked Birnie through an email (asked PD to forward my query on to him) this morning about clarifying what he was saying in the webinar yesterday. Nothing back yet on that but they've put this out.
Maybe there's a bunch of queries on mobile testing after the webinar yesterday and this is an attempt to bat them off.
@ TGoodland
I spotted this earlier and been chatting with PrimerDesign about it today.
Currently the q16 can run 14 samples in around 2 hours (not 16 as two wells have to be controls, one + and one -).
There's no downtime between cycles, you can immediately restock it and run the next batch of samples. The fastest you could run 98 samples at the moment would be 14 hours.
This new rapid test will only take 1 hour, so 98 samples would take just 7 hours which is more in line with what you'd expect a technician to work within a care home I suppose.
It's interesting though that the capacity is there to run nearly 200 samples a day if you're doing two shifts on a single little q16 machine! Might be overkill for most care homes as the average size is 20 beds (+ staff). Larger ones have over 50 beds.
NHS Trusts, Airports, financial institutions etc would be better served using the Q32s and rapid testing which is actually slightly quicker than the q16 and does 30 samples (still needs one + and one - control).
Anything else you want me to ask while I've got one of their guys on hook?
Yesterday closed at 296p. If NCYT does just a mere 1.5% today it's a 300p close.
Huge milestone that everyone's been waiting for!
Come on haha.
Jeez nearly 12! You're right, GL for the morning!
@ B2 Honestly at this stage after the webinar, it's just not clear.
The guy to ask is Birnie, he wasn't keen to divulge info today, but he made it sound like it was around the corner. I'll email him tomorrow and see if he'll at least fill us in on that point, worth a shot.
I would agree yes, if this was intended to be a private communication between two parties then it shouldn't be shared. Not the case this time though and yes we have been in discussion after that. Jo has shared more information, and that hasn't been posted because it unintentionally reveals something personal about her and not in our interests.
Again, it's nice to have an ethical stance but it's misplaced here and Jo understands the intention of the question and our interests. It's simply a point of information that is normally included on trial information. Actually a bit odd it was left out earlier, and Jo agrees.
I'm not aware of difficulty you have with companies replying to emails. I find they reply to me fine.
@ B2
YestThat could be their contribution, or something more. Either way it's at least a collaboration and NCYT/PrimerDesign will release information about this soon (Birnie said that in the webinar too in response to a question). They certainly have no bones about talking about mobile testing as if it's their project though. Nothing at all today indicated anyone else was even involved except the NHS Trust come to think about it..
@ B2 That's where things get murky now.
PrimerDesign referred to this mobile test today in the webinar as if it were their own. He was even supposed to be at PrimerDesign's webinar today to cover a talking point.
She knows it's info sought out for a group of us, spoke to her after this.
Generally speaking I don't find this sort of fact finding to be personal myself. Anything that would be compromising would be revealed to a random enquirer and by extension a group of random enquirers. This is a professional communication to an external party.
That said I have had discussions with SP Angel that I haven't posted, because there's stuff in there that really doesn't reflect well on them at all!
I'd asked about the study length earlier in the day and Professor JE Martin kindly replied tonight:
Dear Chris,
The study runs for 40 days (21 active days), but is in sequence as the care homes are recruited. In the event of early differences between the groups there will be review of the data by an independent data group during the study, but we expect the analysis to follow completion.
Hope this helps!
Kind regards
Jo
Prof JE Martin MA PhD RCPathME FRCPath FRCPI(Hon)
President of the Royal College of Pathologists
Professor of Pathology, Queen Mary University of London
Director of Academic Health Sciences, Barts Health NHS Trust
@ Usain_
Oh yes this guy:
https://uk.linkedin.com/in/kiddstephen
Out doing the mobile testing. Clearly a busy man if he can't dial in for 5 minutes on Zoom!
@Usain_ Maybe it's all a bit UK-centric for them?
Even the webinar was English and Spanish.
@gggg21 That's the bit I'm stumped on.
To me it looks like the trial has just started, and the test is wide scale in a community setting. Usually a massive headache to get started administratively and logistically.
But then GM says launch in, well pretty much just a week from now.
I don't see how that gets squared. If it was a two day lab test I'd get it, and even then I'd consider it tight.
I'm thinking this is ready to go as is, and this 'trial' is an installation which if successful will be adopted by the NHS. They'll look at daily feedback and if there's issues, push the launch forward.
That's my thinking, maybe I'm missing something simple. But it doesn't square with me.
Certainly not displeased though. The market having a launch to look forward to by the end of next week's trading is the momentum builder we've been waiting for...
Yeah Usain_ I was wondering about that too recently. We've been hyping up this govt. tender and then if we don't get it, it would be a hard day for the share price.
Much more confident now. Novacyt's basically been in bed with the UK govt. from the start. They worked together to make centralised, then localised testing a reality in the UK. To date we don't have competition at this level, there's only Novacyt and Roche who has this standard of kit.
The chances fo PrimerDesign putting in a tender for antigen testing and being turned down. Personally I'd say that was super slim. Much more likely we get as much as we can handle. Also PHE and local trusts know about the various testing NCYT is doing, ie. mobile etc. That's because it's actually those NHS trusts and UK universities that carry out the tests! The Hampshire NHS Trust doc is out testing PrimerDesigns mobile kit as we speak.
Oh but just as I was logging out I did understand one thing. Rodriguez was saying, 'test, test, test'.
Haha. So the sales pitch was coming after all!
Questions now.
First is about mobile testing and care homes.
Dr. Stephen isn't there today because he's actually out testing mobile testing as we speak. This mobile testing information will be available shortly but not today (shame, but yes, mobile testing is on and being tested!)
They've decided to skip the rest of questions and have them all sent and responded to by writing. They will end the session in English now and continue in Spanish now. Rodriguez has taken over now and is talking to the Mexican and Spanish speaking markets.
That's all for me. I'm too thick to speak another language!